Search

Your search keyword '"Chiche, L"' showing total 1,379 results
Start Over Author "Chiche, L"
1,379 results on '"Chiche, L"'

1. Outcome and prognosis of isolated carotid vasculitis

Author

Hankard, A., Maalouf, G., Laouni, J., Espitia, O., Agard, C., De Boysson, H., Aouba, A., Sacré, K., Papo, T., Leroux, G., Vautier, M., Desbois, A.C., Domont, F., Le Joncour, A., Mirouse, A., Chiche, L., Skaff, Y., Gaudric, J., Boussouar, S., Redheuil, A., Bravetti, M., Cacoub, P., and Saadoun, D.

Published
2024
Full Text
View/download PDF

4. OP0261 ASSESSMENT OF THE REMISSION MAINTENANCE AFTER TOCILIZUMAB WITHDRAWAL IN POLYMYALGIA RHEUMATICA PATIENTS RECEIVING A 6-MONTH TREATMENT

Author

Chevet, B., primary, Aghiles, S., additional, Emmanuel, N., additional, Carvajal Alegria, G., additional, Dernis, E., additional, Richez, C., additional, Truchetet, M. E., additional, Wendling, D., additional, Toussirot, E., additional, Perdriger, A., additional, Gottenberg, J. E., additional, Felten, R., additional, Fautrel, B., additional, Lohse, A., additional, Chiche, L., additional, Hilliquin, P., additional, Le Henaff Bourhis, C., additional, Benjamin, D., additional, Direz, G., additional, Chary-Valckenaere, I., additional, Cornec, D., additional, Guellec, D., additional, Marhadour, T., additional, Saraux, A., additional, and Devauchelle-Pensec, V., additional

Published
2024
Full Text
View/download PDF

5. OP0123 INFLIXIMAB VERSUS CYCLOPHOSPHAMIDE FOR SEVERE BEHÇET’S SYNDROME

Author

Saadoun, D., primary, Maalouf, G., additional, Vieira, M., additional, Trad, S., additional, Lazaro, E., additional, Sacre, K., additional, Plessier, A., additional, Sené, T., additional, Koné-Paut, I., additional, Noel, N., additional, Mekinian, A., additional, Lambert, M., additional, Ribeiro, E., additional, Mirault, T., additional, Mele, N., additional, Dellal, A., additional, Fain, O., additional, Melki, I., additional, Chiche, L., additional, Gaudric, J., additional, Redheuil, A., additional, Maillart, E., additional, Ghembaza, A., additional, Desbois, A. C., additional, Mirouse, A., additional, Domont, F., additional, Leroux, G., additional, Ferfar, Y., additional, Rigolet, A., additional, Viallard, J. F., additional, Vautier, M., additional, Resche-Rigon, M., additional, and Cacoub, P., additional

Published
2024
Full Text
View/download PDF

8. Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach

Author

Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S, Pegliasco H, Le Treut J, Grisoni V, Coquet E, Chiche L, and Rognon A

Subjects
immunotherapy, elderly, pd-1 inhibitor, pdl-1 inhibitor, safety, immune-related adverse events, solid tumours, prognostic biomarkers., Therapeutics. Pharmacology, RM1-950
Abstract

Fabien Grimaud,1 Guillaume Penaranda,2 Chloé Stavris,3 Frédérique Retornaz,3 Véronique Brunel,4 Sylvie Cailleres,4 Hervé Pegliasco,5 Jacques Le Treut,5 Vincent Grisoni,6 Emilie Coquet,1 Laurent Chiche,3 Amélie Rognon1 1Department of Pharmacy, Hôpital Européen, Marseille, France; 2Department of Biostatistics, Hôpital Européen, Marseille, France; 3Department of Internal Medicine, Hôpital Européen, Marseille, France; 4Department of Haemato-Oncology, Hôpital Européen, Marseille, France; 5Department of Pulmonology, Hôpital Européen, Marseille, France; 6Department of Urology, Hôpital Européen, Marseille, FranceCorrespondence: Amélie RognonDepartment of Pharmacy, Hôpital Européen, 6 Rue Désirée Clary, Marseille, 13003, FranceTel +33 4 13 42 73 00Fax +33 4 13 42 76 80Email a.rognon@hopital-europeen.frAim: To assess the efficacy and tolerance of programmed death-1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors and the impact of a standardised management-based protocol in a real-world setting.Patients and Methods: Data from patients who had received anti-PD-(L)1 were collected from our pharmacy database. Clinical response and toxicity were assessed using RECIST criteria and CTCAE version 5.0, respectively. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method. Potential prognostic factors were identified using Cox’s model.Results: A total of 196 patients and 201 lines of treatment were included (median age: 66 (range: 38– 89) years). Types of cancer included non-small cell lung cancer (73%), transitional cell carcinoma (10%), renal cell carcinoma (6%), small cell lung cancer (5%), head and neck squamous cell carcinoma (4%) and classical Hodgkin’s lymphoma (1%). Twenty-five (12%) patients had pre-existing autoimmune conditions. Our standardised management-based protocol included 129 (64%) patients. Objective response rate was 29%, median OS was 10 months (IQR: 7– 15) and median PFS was 5 months (IQR: 1– 22). Patients with an abnormal baseline complete blood count had a worse OS (HR=2.48 [95% CI: 1.24– 4.96]; p=0.0103). Thirty-three (16%) patients experienced severe (grade 3 or 4) immune-related adverse event (irAE). There were three (1%) irAE-related deaths. AEs resolved faster when patients were assessed by an internist before anti-PD-(L)1 initiation (p=0.0205).Conclusion: PD-1 and PD-L1 inhibitors are effective and safe in a real-world setting. Implementation of a standardised management-based protocol with internal medicine specialists is an effective way to optimise irAE management.Keywords: immunotherapy, elderly, PD-1 inhibitor, PD-L1 inhibitor, PDL-1 inhibitor, safety, immune-related adverse events, solid tumours, prognostic biomarkers

Published
2021

12. Influence of 4 preservation solutions on ICU stay, graft and patient survival following liver transplantation

Author

Mallet, A., Cherqui, D., Adam, R., Ciacio, O., Pittau, G., Trechot, B., Boudjema, K., Houssel-Debry, P., Merdignac, A., Rayar, M., Soubrane, O., Dokmak, S., Dondero, F., Sepulveda, A., Bachellier, P., Addeo, P.-F., Faitot, F., Navarro, F., Herrero, A., Jaber, S., Pageaux, G.-P., Vaillant, J.-C., Rousseau, G., Siksik, J.-M., Le Treut, Y.P., Gregoire, E., Hardwigsen, J., Compagnon, P., Lim, C., Salloum, C., Chirica, M., Abba, J., Letoublon, C., Pruvot, F.-R., Boleslawski, E., Salame, E., Barbier, L., Mabrut, J.Y., Mohkam, K., Suc, B., Maulat, C., Chiche, L., Laurent, C., Jeune, F., Perdigao, F., Dao, T., Mulliri, A., Gugenheim, J., Boilot, O., Buc, E., Branchereau, S., Chardot, C., Heyd, B., Savier, E., Brustia, R., Golmard, J.-L., and Scatton, O.

Published
2020
Full Text
View/download PDF

13. Influence de 4 solutions de préservation sur la durée de réanimation, la survie du greffon et du patient après transplantation hépatique

Author

Mallet, A., Cherqui, D., Adam, R., Ciacio, O., Pittau, G., Trechot, B., Boudjema, K., Houssel-Debry, P., Merdignac, A., Rayar, M., Soubrane, O., Dokmak, S., Dondero, F., Sepulveda, A., Bachellier, P., Addeo, P.-F., Faitot, F., Navarro, F., Herrero, A., Jaber, S., Pageaux, G.-P., Vaillant, J.-C., Rousseau, G., Siksik, J.-M., Le Treut, Y.P., Gregoire, E., Hardwigsen, J., Compagnon, P., Lim, C., Salloum, C., Chirica, M., Abba, J., Letoublon, C., Pruvot, F.-R., Boleslawski, E., Salame, E., Barbier, L., Mabrut, J.Y., Mohkam, K., Suc, B., Maulat, C., Chiche, L., Laurent, C., Jeune, F., Perdigao, F., Dao, T., Mulliri, A., Gugenheim, J., Boilot, O., Buc, E., Branchereau, S., Chardot, C., Heyd, B., Savier, E., Brustia, R., Golmard, J.-L., and Scatton, O.

Published
2020
Full Text
View/download PDF

15. Traitement d’induction par infliximab versus cyclophosphamide dans le syndrome de Behçet sévère : essai (ITAC) randomisé, contrôle, multicentrique de phase 2

Author

Maalouf, G., primary, Vieira, M., additional, Trad, S., additional, Lazaro, E., additional, Sacre, K., additional, Plessier, A., additional, Thomas, S., additional, Kone-Paut, I., additional, Nicolas, N., additional, Mekinian, A., additional, Lambert, M., additional, Jean-François, V., additional, Ribeiro, E., additional, Mirault, T., additional, Mele, N., additional, Dellal, A., additional, Fain, O., additional, Melki, I., additional, Chiche, L., additional, Gaudric, J., additional, Redheuil, A., additional, Maillart, E., additional, Vautier, M., additional, Anne-Claire, D., additional, Mirouse, A., additional, Domont, F., additional, Leroux, G., additional, Ferfar, Y., additional, Rigolet, A., additional, Cacoub, P., additional, Mathieu, R.R., additional, and Saadoun, D., additional

Published
2023
Full Text
View/download PDF

17. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool

Author

Piñero, F, Costentin, C, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Carrilho, F, Cherqui, D, Burra, P, Van Vlierberghe, H, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Costa, P, de Ataide, E, Quiñones, E, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Podestá, L, Mccormack, L, Mattera, J, Gadano, A, Parente García, J, Magini, G, Miglioresi, L, Gambato, M, D'Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Piñero F., Costentin C., Degroote H., Notarpaolo A., Boin I. F., Boudjema K., Baccaro C., Chagas A., Bachellier P., Ettorre G. M., Poniachik J., Muscari F., Dibenedetto F., Duque S. H., Salame E., Cillo U., Marciano S., Vanlemmens C., Fagiuoli S., Carrilho F., Cherqui D., Burra P., Van Vlierberghe H., Lai Q., Silva M., Rubinstein F., Duvoux C., Conti F., Scatton O., Bernard P. H., Francoz C., Durand F., Dharancy S., Woehl M. l., Laurent A., Radenne S., Dumortier J., Abergel A., Barbier L., Houssel-Debry P., Pageaux G. P., Chiche L., Deledinghen V., Hardwigsen J., Gugenheim J., altieri M., Hilleret M. N., Decaens T., Costa P., de Ataide E. C., Quiñones E., Anders M., Varón A., Zerega A., Soza A., Machaca M. P., Arufe D., Menéndez J., Zapata R., Vilatoba M., Muñoz L., Menéndez R. C., Maraschio M., Podestá L. G., McCormack L., Mattera J., Gadano A., Parente García J. H., Magini G., Miglioresi L., Gambato M., D'Ambrosio C., Vitale A., Colledan M., Pinelli D., Magistri P., Vennarecci G., Colasanti M., Giannelli V., Pellicelli A., Eduard C., Samuele I., Jeroen D., Jonas S., Jacques P., Chris V., Dirk Y., Peter M., Valerio L., Christophe M., Olivier D., Jean D., Roberto T., Paul L. J., Piñero, F, Costentin, C, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Carrilho, F, Cherqui, D, Burra, P, Van Vlierberghe, H, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Costa, P, de Ataide, E, Quiñones, E, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Podestá, L, Mccormack, L, Mattera, J, Gadano, A, Parente García, J, Magini, G, Miglioresi, L, Gambato, M, D'Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Piñero F., Costentin C., Degroote H., Notarpaolo A., Boin I. F., Boudjema K., Baccaro C., Chagas A., Bachellier P., Ettorre G. M., Poniachik J., Muscari F., Dibenedetto F., Duque S. H., Salame E., Cillo U., Marciano S., Vanlemmens C., Fagiuoli S., Carrilho F., Cherqui D., Burra P., Van Vlierberghe H., Lai Q., Silva M., Rubinstein F., Duvoux C., Conti F., Scatton O., Bernard P. H., Francoz C., Durand F., Dharancy S., Woehl M. l., Laurent A., Radenne S., Dumortier J., Abergel A., Barbier L., Houssel-Debry P., Pageaux G. P., Chiche L., Deledinghen V., Hardwigsen J., Gugenheim J., altieri M., Hilleret M. N., Decaens T., Costa P., de Ataide E. C., Quiñones E., Anders M., Varón A., Zerega A., Soza A., Machaca M. P., Arufe D., Menéndez J., Zapata R., Vilatoba M., Muñoz L., Menéndez R. C., Maraschio M., Podestá L. G., McCormack L., Mattera J., Gadano A., Parente García J. H., Magini G., Miglioresi L., Gambato M., D'Ambrosio C., Vitale A., Colledan M., Pinelli D., Magistri P., Vennarecci G., Colasanti M., Giannelli V., Pellicelli A., Eduard C., Samuele I., Jeroen D., Jonas S., Jacques P., Chris V., Dirk Y., Peter M., Valerio L., Christophe M., Olivier D., Jean D., Roberto T., and Paul L. J.

Abstract

Background & Aims: Two recently developed composite models, the alpha-fetoprotein (AFP) score and Metroticket 2.0, could be used to select patients with hepatocellular carcinoma (HCC) who are candidates for liver transplantation (LT). The aim of this study was to compare the predictive performance of both models and to evaluate the net risk reclassification of post-LT recurrence between them using each model's original thresholds. Methods: This multicenter cohort study included 2,444 adult patients who underwent LT for HCC in 47 centers from Europe and Latin America. A competing risk regression analysis estimating sub-distribution hazard ratios (SHRs) and 95% CIs for recurrence was used (Fine and Gray method). Harrell's adapted c-statistics were estimated. The net reclassification index for recurrence was compared based on each model's original thresholds. Results: During a median follow-up of 3.8 years, there were 310 recurrences and 496 competing events (20.3%). Both models predicted recurrence, HCC survival and survival better than Milan criteria (p <0.0001). At last tumor reassessment before LT, c-statistics did not significantly differ between the two composite models, either as original or threshold versions, for recurrence (0.72 vs. 0.68; p = 0.06), HCC survival, and overall survival after LT. We observed predictive gaps and overlaps between the model's thresholds, and no significant gain on reclassification. Patients meeting both models (“within-ALL”) at last tumor reassessment presented the lowest 5-year cumulative incidence of HCC recurrence (7.7%; 95% CI 5.1-11.5) and higher 5-year post-LT survival (70.0%; 95% CI 64.9-74.6). Conclusions: In this multicenter cohort, Metroticket 2.0 and the AFP score demonstrated a similar ability to predict HCC recurrence post-LT. The combination of these composite models might be a promising clinical approach. Impact and implications: Composite models were recently proposed for the selection of liver transplant (LT

Published
2023

21. Une cause rare de cécité

Author

Escoda, T., primary, Stavris, C., additional, Genot, S., additional, Thomas, G., additional, Retornaz, F., additional, and Chiche, L., additional

Published
2023
Full Text
View/download PDF

23. Les anti-CD20 : principal facteur prédictif de réponse vaccinale humorale et cellulaire dans une cohorte de patients atteints de diverses affections dysimmunitaires : une étude prospective en vie réelle

Author

Escoda, T., primary, Jordana, S., additional, Chiche, L., additional, Delord, M., additional, Genot, S., additional, Stavris, C., additional, Retornaz, F., additional, Penaranda, G., additional, Rebaudet, S., additional, and Halfon, P., additional

Published
2023
Full Text
View/download PDF

24. POS0969 PREDICTIVE FACTORS OF FAVOURABLE EVOLUTION IN GLUCOCORTICOIDS-DEPENDENT POLYMYALGIA RHEUMATICA

Author

Boukhlal, S., primary, Aghiles, S., additional, Emmanuel, N., additional, Carvajal Alegria, G., additional, Dernis, E., additional, Richez, C., additional, Direz, G., additional, Chary Valckenaere, I., additional, Truchetet, M. E., additional, Wendling, D., additional, Toussirot, E., additional, Perdriger, A., additional, Gottenberg, J. E., additional, Felten, R., additional, Fautrel, B., additional, Chiche, L., additional, Hilliquin, P., additional, Le Henaff Bourhis, C., additional, Benjamin, D., additional, Lohse, A., additional, Guellec, D., additional, Marhadour, T., additional, Pochard, P., additional, Cornec, D., additional, Saraux, A., additional, and Devauchelle-Pensec, V., additional

Published
2023
Full Text
View/download PDF

26. POS0718 IS IT POSSIBLE TO EVALUATE POLYMYALGIA RHEUMATICA WITHOUT CRP? CONCORDANCE AND AGREEMENT BETWEEN DIFFERENT PMR-AS ACTIVITY SCORES IN POLYMYALGIA RHEUMATICA

Author

Justine, D., primary, Aghiles, S., additional, Lohse, A., additional, Carvajal Alegria, G., additional, Dernis, E., additional, Richez, C., additional, Truchetet, M. E., additional, Wendling, D., additional, Toussirot, E., additional, Perdriger, A., additional, Gottenberg, J. E., additional, Fautrel, B., additional, Chiche, L., additional, Hilliquin, P., additional, Le Henaff Bourhis, C., additional, Benjamin, D., additional, Direz, G., additional, Chary Valckenaere, I., additional, Cornec, D., additional, Guellec, D., additional, Marhadour, T., additional, Emmanuel, N., additional, Saraux, A., additional, and Devauchelle-Pensec, V., additional

Published
2023
Full Text
View/download PDF

40. Sudoscan as a noninvasive tool to assess sudomotor dysfunction in patients with Fabry disease: results from a case–control study

Author

Sahuc P, Chiche L, Dussol B, Pouget J, and Franques J

Subjects
Electrochemical skin conductance, small fiber neuropathy, Fabry disease, sweat dysfunction, hypohidrosis, Therapeutics. Pharmacology, RM1-950
Abstract

Pauline Sahuc,1 Laurent Chiche,2 Bertrand Dussol,3 Jean Pouget,1 Jérôme Franques1,2,4 1Department of Neurology, La Timone Hospital, APHM, Aix-Marseille University, 2Department of Internal Medicine, European Hospital, 3Department of Nephrology, La Conception Hospital, APHM, Aix-Marseille University, 4Department of Neurology, La Casamance Hospital, Marseille, France Abstract: Hypohidrosis is a frequent and early symptom in patients with Fabry disease. Studies have reported improved sweating in patients treated with enzyme-replacement therapy. A new method, Sudoscan, has been developed that is noninvasive, is quantitative, and can quickly evaluate sweat gland function. It is based on the electrochemical reaction between sweat chlorides and stainless-steel electrodes in contact with the palms and soles. The aim of our study was to evaluate the Sudoscan as a tool to assess sudomotor dysfunction in patients with Fabry disease. Consecutive patients were prospectively recruited who had a diagnosis of Fabry disease, which had been confirmed genetically and/or by measurement of α-galactosidase activity in leukocytes. Healthy controls, matched (1:1) for age and sex, were also enrolled. Test results were expressed immediately as electrochemical skin conductance (ESC, µS) for hands and feet. Sudomotor dysfunction was considered absent, moderate, or severe if the ESC measured on the feet was >60 µS, between 60 and 40 µS, or

Published
2016

42. Efficacité du Tocilizumab chez les patients ayant une Pseudo Polyarthrite Rhizomélique active malgré un traitement par corticothérapie : une étude thérapeutique randomisée

Author

Devauchelle Pensec, V., primary, Carvajal Alegria, G., additional, Dernis, E., additional, Richez, C., additional, Truchetet, M.E., additional, Wendling, D., additional, Toussirot, É., additional, Perdriger, A., additional, Gottenberg, J.E., additional, Felten, R., additional, Fautrel, B., additional, Chiche, L., additional, Hilliquin, P., additional, Le Henaff, C., additional, Dervieux, B., additional, Direz, G., additional, Chary Valckenaere, I., additional, Cornec, D., additional, Guellec, D., additional, Marhadour, T., additional, Nowak, E., additional, and Saraux, A., additional

Published
2022
Full Text
View/download PDF

43. Est-il possible d’évaluer la pseudopolyarthrite rhizomélique sans CRP ? Concordance et corrélation entre différents scores d’activité DAS-PPR dans la pseudopolyarthrite rhizomélique

Author

D’agostino, J., primary, Saraux, A., additional, Carvajal Alegria, G., additional, Dernis, E., additional, Richez, C., additional, Truchetet, M.E., additional, Wendling, D., additional, Toussirot, É., additional, Perdriger, A., additional, Gottenberg, J.E., additional, Felten, R., additional, Fautrel, B., additional, Chiche, L., additional, Hilliquin, P., additional, Le Henaff, C., additional, Dervieux, B., additional, Direz, G., additional, Chary-Valckenaere, I., additional, Cornec, D., additional, Guellec, D., additional, Marhadour, T., additional, Souki, A., additional, Nowak, E., additional, and Devauchelle Pensec, V., additional

Published
2022
Full Text
View/download PDF

48. Facteurs prédictifs d’évolution favorable de la pseudo-polyarthrite rhizomélique corticodépendante

Author

Boukhlal, S., primary, Souki, A., additional, Nowak, E., additional, Carvajal Alegria, G., additional, Dernis, E., additional, Richez, C., additional, Direz, G., additional, Chary Valckenaere, I., additional, Truchetet, M.E., additional, Wendling, D., additional, Toussirot, É., additional, Perdriger, A., additional, Gottenberg, J.E., additional, Felten, R., additional, Fautrel, B., additional, Chiche, L., additional, Hilliquin, P., additional, Le Henaff, C., additional, Dervieux, B., additional, Guellec, D., additional, Marhadour, T., additional, Cornec, D., additional, Saraux, A., additional, and Devauchelle Pensec, V., additional

Published
2022
Full Text
View/download PDF

49. The Value of Abdominal Drainage After Laparoscopic Cholecystectomy for Mild or Moderate Acute Calculous Cholecystitis: A Post Hoc Analysis of a Randomized Clinical Trial

Author

Prevot, Flavien, Fuks, David, Cosse, Cyril, Pautrat, Karine, Msika, Simon, Mathonnet, Muriel, Khalil, Haitham, Mauvais, François, Regimbeau, Jean-Marc, Arnaud, J. P., Arvieux, C., Bonnetain, F., Chiche, L., Collet, D., Haccart, V., Lacaine, F., Millat, B., Paquet, J. C., Sielezneff, I., Slim, K., Vons, C., and the FRENCH Cholecystitis Working Group

Published
2016
Full Text
View/download PDF

50. Quand le loup sème le doute, le cochon perd la foi

Author

Stavris, C., primary, Chiche, L., additional, Charpin, C., additional, Dukan, P., additional, Doncarli, C., additional, Drouet, H., additional, Delord, M., additional, Renard, L., additional, Allemand, J., additional, Caillères, S., additional, Talbi, N., additional, Halfon, P., additional, Retornaz, F., additional, and Servettaz, A., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results